Curran T, Sun Z, Gerry B, Findlay VJ, Wallace K, Li Z, Paulos C, Ford ME, Rubinstein MP, Chung D and Camp ER. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Medicine (accepted).
Garcia D, Hurst K, Wang C, Janakariman H, Bradshaw A, and Camp ER. High Fat-Induced Obese Conditions Drive an Aggressive Pancreatic Cancer Phenotype. (accepted Journal of Surgical Research)
Janakiraman1 H, Zhu Y, Becker SA, Wang C, Cross A, Curl E, Lewin D, Hoffman BJ, Warren GW, Hill EG, Timmers C, Findlay VJ, and Camp ER. Modeling rectal cancer to advance neoadjuvant precision therapy. International Journal of Cancer 2020.
Zhu Y, Wang C, Becker SA, Hurst K, Nogueira LM, Findlay VJ and Camp ER. miR-145 antagonizes SNAI1-mediated stemness and radiation resistance in colorectal cancer. Molecular Therapeutics. 2018 Mar 7;26(3):744-754.
Riley JM, Cross AW, Paulos C, Rubinstein MP, Wrangle J, and Camp ER. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer. 2018 Apr 15;124(8):1650-1659.
Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, and Camp ER. Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. Oncology Reviews. 2019 Aug 1;13 (2):430.
Findlay VJ, Wang C, Quirk D, Hurst K, Vaena S, Watson DK, and Camp ER. SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Molecular Cancer Therapeutics 2014, 13(11): 2713-26.